The National Institutes of Health awarded nearly $470 million to build a national study population of diverse research volunteers and support large-scale studies on the long-term effects of COVID-19. The NIH Researching COVID to Enhance Recovery (RECOVER) Initiative made the parent award to New York University (NYU) Langone Health, New York City,...
To support people of all ages who have experienced the lingering effects of COVID-19, researchers are collecting and analyzing data from patients at different points of infection. This ongoing research and classification of “long COVID” will guide future treatment and prevention strategies.
Researchers are reporting that an intensive lifestyle modification program that includes the DASH diet combined with exercise can significantly reduce blood pressure in patients with “resistant” hypertension.
A small study found that young adults with heritable forms of hypertrophic cardiomyopathy who received valsartan, a drug used to treat high blood pressure and heart failure, tolerated the treatment and were less likely to experience changes in cardiovascular structure and function.
A collaborative framework to reduce added sugar from the U.S. food supply could help food service providers and public health experts work together to improve the cardiovascular health outcomes of Americans, which could save money and add years to lives.
After following 144,336 veterans for years, researchers found adults living with HIV had a higher associated risk of sudden cardiac death compared to adults living without HIV. These associated risks increased among adults with higher loads of the virus and who had compromised immune function.
A healthy sleep pattern has long been associated with good cardiovascular health. Now, new research has linked healthy sleep with significantly lower risk of developing atrial fibrillation and other cardiac arrhythmias.
After studying lung infection rates among New York City firefighters who served as first responders at the World Trade Center on Sept. 11, 2001 and were exposed to tiny air pollution particles, researchers identified factors that overlapped with lung infection risks.
A phase 3 trial found using colchicine reduced death and hospitalization rates among adults with COVID-19 recovering at home, but only if they had a positive test result. More research is necessary to assess the benefits of using this anti-inflammatory treatment for moderate COVID-19 cases.